Combined GPR40 and GPR119 full agonism with K‐757 and K‐833 results in robust glucose lowering and modest weight loss in overweight/obese subjects with T2DM
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.70014 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Michael Crutchlow und 8 weiteren Autor:innen. Beteiligte Einrichtung: Kallyope, Inc., New York, New York, USA. Hauptthemen laut MEDLINE: Receptors, G-Protein-Coupled, Diabetes Mellitus, Type 2, Obesity, Weight Loss. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
Aims
K‐757 and K‐833 are novel full agonists of GPR40 and GPR119, respectively, which are nutrient receptors co‐expressed on both pancreatic beta cells and gut enteroendocrine cells that signal through complementary mechanisms. We sought to assess the effects on glucose control and body weight following co‐administration of K‐757 and K‐833. Materials and Methods We conducted two randomized, double‐blind, placebo‐controlled Phase 1 studies in overweight‐obese subjects with T2DM maintained on metformin to characterize the effects on secretion of gut incretin and appetite‐regulating hormones, glucose control and body weight following combined therapy with K‐757 and K‐833. In Study 1 (28 days in duration) K‐757/K‐833 was titrated to 60/100 mg BID. In Study 2 (42 days in duration) K‐757/K‐833 was titrated to 240/200 mg QD.
Results
Twenty‐five subjects were enrolled in Study 1 (12 on placebo and 13 on K‐757 + K‐833) and 24 in Study 2 (6 on placebo and 18 on K‐757 + K‐833). By design, baseline A1C was higher in Study 1 compared with Study 2. After 28 days of dosing (Study 1), the combination of K‐757 + K‐833 resulted in placebo‐corrected LS mean reductions from baseline in 24 h‐WMG, FPG, A1C and body weight of 77.3 mg/dL, 64.0 mg/dL, 0.55% and 1.61%, respectively. After 42 days of dosing (Study 2), the combination of K‐757 + K‐833 resulted in placebo‐corrected LS mean reductions from baseline in FPG, A1C and body weight of 25.2 mg/dL, 0.26% and 4.95%, respectively.
Conclusions
Co‐agonism of GPR40 and GPR119 with K‐757 and K‐833 elicits rapid, robust and glucose‐dependent glucose lowering and modest weight loss in patients with T2DM on stable metformin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Kallyope, Inc., New York, New York, USA.
- QPS, LLC, Miramar, Florida, USA.
ORCID-Profile: Brett Lauring
Zitieren
APA
Crutchlow, M., Liu, J., Hernandez-Illas, M., Zhang, H., Arreglado, A., Vance, A., Boisvert, D., Terracina, G., & Lauring, B. (2025). Combined GPR40 and GPR119 full agonism with K‐757 and K‐833 results in robust glucose lowering and modest weight loss in overweight/obese subjects with T2DM. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70014
Vancouver
Crutchlow M, Liu J, Hernandez-Illas M, Zhang H, Arreglado A, Vance A, et al. Combined GPR40 and GPR119 full agonism with K‐757 and K‐833 results in robust glucose lowering and modest weight loss in overweight/obese subjects with T2DM. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.70014
BibTeX
@article{Crutchlow2025,
author = {Crutchlow, Michael and Liu, Jiajun and Hernandez-Illas, Martha and Zhang, Harry and Arreglado, Anna and Vance, Annemarie and Boisvert, Daniel and Terracina, Giuseppe and Lauring, Brett},
title = {Combined GPR40 and GPR119 full agonism with K‐757 and K‐833 results in robust glucose lowering and modest weight loss in overweight/obese subjects with T2DM},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.70014}
}
EUVIMED